Hepatocellular Carcinoma

New data indicate that circulating microRNAs may increased risk for hepatocellular carcinoma among patients with chronic hepatitis C-related cirrhosis and a sustained virologic response.

Patients with hepatocellular carcinoma who live in rural regions or lower-income households had more advanced disease at diagnosis and higher disease-related mortality than other patients, according to study results published in Cancer.

The FDA granted fast track designation to SRF388 for treatment of certain patients with hepatocellular carcinoma, according to the agent’s manufacturer.

Compared with men, women had a significantly higher frequency of underlying nonalcoholic fatty liver disease and noncirrhotic hepatocellular carcinoma, according to data published in the American Journal of Gastroenterology.

Chronic liver diseases, including decompensated cirrhosis and hepatocellular carcinoma, were associated with increased mortality in patients with COVID-19, according to study results.

Among patients with hepatocellular carcinoma who first failed Retevmo, Stivarga and Opdivo provided similar outcomes in terms of survival as second-line treatments, according to research presented at The Digital International Liver Congress.

Hepatocellular carcinoma, the sixth most common cancer, accounts for 90% of primary liver cancers worldwide. Its incidence has tripled since the 1980s.

Consumption of caffeinated coffee does not appear to increase risk for various cancer types, according to a review article published in The New England Journal of Medicine.

Hepatocellular carcinoma is one of the few cancers in the United States that has been increasing in incidence and mortality rates over the last three decades.

A single 300 mg priming dose of tremelimumab in combination with durvalumab appeared safe and active among patients with advanced hepatocellular carcinoma, according to study results presented during the ASCO20 Virtual Scientific Program.